Clinical Data Survodutide delivers 16.6% weight loss in major phase 3 obesity trial PharmaTimesBoehringer Ingelheim reports significant reductions in weightMetabolic & GLP-1Read full story pharminent April 30, 2026 (Last updated: April 30, 2026) PharmaTimes Boehringer Ingelheim reports significant reductions in weight Metabolic & GLP-1 Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Avalyn, in pursuit of better lung drugs, banks $300M in an IPONext: Ray Therapeutics receives EMA PRIME status for gene therapy Related Stories Clinical Data Lilly’s Verve gambit pays off as base editor cuts cholesterol in early study pharminent May 26, 2026 Clinical Data Parkinson’s drug from Biogen, Denali comes up short pharminent May 22, 2026 Clinical Data Kelun-Merck validate TROP2-Keytruda pairing in lung cancer with improved survival pharminent May 22, 2026
